论文部分内容阅读
目的:观察肾方联合免疫抑制剂对急性再生障碍性贫血的治疗效果以及对可能影响用药效果的因素进行分析。方法:选取60例再生障碍性贫血患者,根据治疗方式分为观察组和治疗组,对照组患者应用抗胸腺细胞球蛋白(ATG)和环孢霉素A(Cs A)治疗,观察组在对照组基础上加用补肾中药治疗。结果:观察组患者治疗后白细胞(WBC)、血小板(PL)、血红蛋白(Hb)、CD8+、CD4+/CD8+、CD(16+56+)与对照组相比,差异有统计学意义(P<0.05);治疗有效患者治疗后第2周,第3周和1个月Cs A与治疗无效者差异有统计学意义(P<0.05)。结论:补肾方联合免疫抑制剂对急性再生障碍性贫血治疗效果明显,并且治疗效果与患者起始WBC、CD4+/CD8+、CD(16+56+)水平以及治疗过程中Cs A的量有关。
OBJECTIVE: To observe the therapeutic effect of combined prescription of kidney-kidney immunosuppressant on acute aplastic anemia and to analyze the factors that may influence the effect of the drug. Methods: Sixty patients with aplastic anemia were selected and divided into observation group and treatment group according to the treatment method. Patients in the control group were treated with ATG and CsA, and in the control group, Group based on the use of kidney medicine. Results: The difference of WBC, PL, Hb, CD8 +, CD4 + / CD8 +, CD (16 + 56 +) between the observation group and the control group was statistically significant (P <0.05 ). There was significant difference between CsA and ineffective patients after 2 weeks, 3 weeks and 1 month after treatment (P <0.05). Conclusion: Bushenfang combined with immunosuppressant has a significant effect on the treatment of acute aplastic anemia, and the therapeutic effect is related to the initial WBC, CD4 + / CD8 +, CD (16 + 56) levels and the amount of CsA during the treatment.